Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger
Ligand Pharmaceuticals Inc (NASDAQ: LGND)
Legend Biotech USA Inc. And Janssen Pharmaceuticals, Inc. Enter Into Interim Product Supply Agreement
In connection with the Collaboration and License Agreement dated as of December 21, 2017 between Legend Biotech USA Inc. (“Legend Biotech”) and Janssen Biotech, Inc., Legend Biotech and Janssen
Benchmark Maintains Buy on Ligand Pharmaceuticals, Lowers Price Target to $130
Benchmark analyst Robert Wasserman maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and lowers the price target from $180 to $130.
Earnings Scheduled For February 17, 2022
Companies Reporting Before The Bell
• Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate proceedings, and the week also witnessed presentations at conferences and a couple of initial public offerings.
Ligand And GSK Expand Global Collaboration And License Agreement; Ligand To Receive An Upfront Payment Of $10M And Is Eligible For Development And Regulatory Milestones Up To $67.5M
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK). The expansion will leverage
Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced plans to split into two separate publicly traded companies. One company will feature the OmniAb…
Ligand Pharmaceuticals Q3 EPS $1.58 Beats $1.04 Estimate, Sales $64.83M Beat $55.65M Estimate
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $1.04 by 51.92 percent. This is a 51.92 percent increase over earnings of $1.04 per share